Stryker buys out of OP-1 royalties to Curis:
This article was originally published in Clinica
Executive Summary
Stryker (Kalamazoo, Michigan) is to pay a one-off cash sum of $14m to Curis (Cambridge, Massachusetts) to release itself from the obligation to pay royalties on future sales of its osteogenic protein-1 bone growth factor (OP-1). Stryker will amortise the payment over the next 15 years. The agreement allows Curis to reduce royalty payments it may owe Stryker for sales of the product, which it calls BMP-7 (bone morphogenic protein), in indications other than orthopaedics and dental (eg, kidney disease).
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.